"This is a jumping-off point" for further work to reveal the biological underpinnings of depression, which in turn can guide development of new drugs, said Ashley Winslow, an author of a paper on the work.
Experts said the result is important not only for its specific findings, but also for its demonstration that the study's approach can help uncover clues to the biology of depression, which is largely a mystery.
But no evidence for that result appeared in people of European descent, which is the group studied in the more bountiful results announced today.
"What they're showing is, we're on the way" to finding many more genetic links, said Dr. Douglas Levinson of Stanford University, who didn't participate in the work.
Also Read
The work by Winslow and others identified 15 areas of the human DNA __ the "genome" __ that show signs of harboring genetic variations that affect risk of becoming depressed.
That indicates where scientists can focus on identifying and studying the affected genes, which in turn could reveal what processes go awry to raise the risk of the disease.
Winslow was with pharmaceutical giant Pfizer Inc. When she did the work with researchers from Massachusetts General Hospital and the genetics testing company 23andMe, Inc. She is now at the University of Pennsylvania. Results were released by the journal Nature Genetics.
They provide an important step toward finding all the genes that affect depression, a list he said probably numbers "in the high hundreds."
"It's a markedly better step than I believe anybody has taken before," he said.
He also said the new study's results cannot be used to test people for their risk of developing depression.